categories: Cytoskeleton: Intermediate Filaments, Cytoskeleton: Intermediate Filaments (Human)

Mouse Monoclonal to Cytokeratin 19

A53-B/A2 (IgG2a)

Product No.	Form	Quantity	Price
11-120-C025	purified	0.025 mg	choose region
11-120-C100	purified	0.1 mg	choose region
1B-120-C025	biotin	0.025 mg	choose region
1B-120-C100	biotin	0.1 mg	choose region
A4-120-C025	Alexa Fluor® 488	0.025 mg	choose region
A4-120-C100	Alexa Fluor® 488	0.1 mg	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

Cytokeratins are a subfamily of intermediate filaments and characterized by remarkable biochemical diversity. Cytokeratins are represented in epithelial tissues by at least 20 different polypeptides, molecular weight between 40 kDa and 68 kDa. The individual cytokeratin polypeptides are designated 1 to 20 and divided into the type I (acidic cytokeratins 9-20) and type II (basic to neutral cytokeratins 1-8) families.

Entrez Gene (human): 17q21.2

Specificity

The antibody A53-B/A2 reacts with Rod domain of cytokeratin 19 (40 kDa) in human tissue. Cytokeratin 19 is not expressed in hepatocytes; it is often co-expressed with cytokeratin 7.

Immunogen

MCF-7 human breast adenocarcinoma cell line

Species Reactivity: Human Negative Species:	Applications: Immunohistochemistry (paraffin sections) Flow Cytometry Immunoprecipitation Western Blotting Immunocytochemistry ELISA Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	Product Specific References Karsten U, Papsdorf G, Roloff G, Stolley P, Abel H, Walther I, Weiss H: Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol. 1985 Jun;21(6):733-40. [Abstract] Kasper M, Moll R, Stosiek P, Karsten U: Patterns of cytokeratin and vimentin expression in the human eye. Histochemistry. 1988;89(4):369-77. [Abstract] *Bártek J, Bártková J, Taylor-Papadimitriou J, Rejthar A, Kovarík J, Lukás Z, Vojtĕsek B: Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986 Oct;18(10):565-75. [Abstract]

Species Reactivity:

Human

Negative Species:

Applications:

Immunohistochemistry (paraffin sections)
Flow Cytometry
Immunoprecipitation
Western Blotting
Immunocytochemistry
ELISA

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

*Karsten U, Papsdorf G, Roloff G, Stolley P, Abel H, Walther I, Weiss H: Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol. 1985 Jun;21(6):733-40. [Abstract]

*Kasper M, Moll R, Stosiek P, Karsten U: Patterns of cytokeratin and vimentin expression in the human eye. Histochemistry. 1988;89(4):369-77. [Abstract]

*Bártek J, Bártková J, Taylor-Papadimitriou J, Rejthar A, Kovarík J, Lukás Z, Vojtĕsek B: Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986 Oct;18(10):565-75. [Abstract]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG2a Isotype Control

Example Data

Fig. 1. Western Blotting

Fig. 1. Western Blotting analysis (reducing conditions) of whole cell lysate of MCF-7 human breast adenocarcinoma cell line.
Lane 1,2: immunostaining with anti-human Cytokeratin 19 (BA-17; cat. no. 11-119-C100)
Lane 3,4: immunostaining with anti-human Cytokeratin 19 (A53-B/A2)

Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registred trademarks of Molecular Probes Inc., Eugene, OR, USA. (licence label)

DyLight™ is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Cy5, Cy5.5 and Cy7 conjugates are made and sold under license from GE Healthcare Bio-Sciences Corp. The conjugates are licensed for non-commercial research use only. Not for therapeutic or in vivo applications. Other use needs license from GE Healthcare Bio-Sciences Corp. under U.S. patent Nos. 5 569 587 and 5 627 027 and other patents pending.

PRODUCTS